The Comparative Bioavailability of a Generic and the Innovator Fluconazole Preparations in Healthy Thai Volunteers

Journal of the Medical Association of Thailand

Volumn 81, Issue 10, 1998, Pages 772-777

  Teekachunhatean, Supanimit ^a   Rojanastein, Noppamas ^a   Manorot, Maleeya ^a   Sangdee, Chaichan ^a   Apisariyakul, Amphawan ^a   Ajayutphokin, Udomchai ^a  

^a Faculty of Medicine Chiang Mai University   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

FLUCONAZOLE; GENERIC DRUG;

ADULT; ANTIFUNGAL ACTIVITY; AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG ABSORPTION; DRUG EFFECT; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; RANDOMIZED CONTROLLED TRIAL; THAILAND;

ADULT; ANALYSIS OF VARIANCE; ANTIFUNGAL AGENTS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CONFIDENCE INTERVALS; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DRUGS, GENERIC; FEMALE; FLUCONAZOLE; HUMANS; MALE; THAILAND;

EID: 0031740433     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (14)

1. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10-27.
2. Force RW, Nahata MC. Salivary concentrations of ketoconazole and fluconazole: implications for drug efficacy in oropharyngeal and esophageal candidiasis. Ann Pharmacother 1995; 29: 10-5.
3. Fromtling RA. Fluconazole (Diflucan®): a new antifungal triazole. Drugs Today 1990; 26: 547-56.
4. Foulds G, Brennan DR, Wajszczuk C, et al. Fluconazole penetration into cerebrospinal fluid in humans. J Clin Pharmacol 1988; 28: 363-6.
5. Washton H. Reveiw of fluconazole: a new triazole antifungal agent. Diag Microbiol Infect Dis 1989; 12: 229S-3S.
6. Houang ET, Chappatte O, Byme D, Macrae PV, Thorpe JE. Fluconazole levels in plasma and vaginal secretions of patients after a 150-milligram single oral dose and rate of eradication of infection in vaginal candidiasis. Antimicrob Agents Chemother 1990; 34: 909-10.
7. Humphreys MJ, Jevons S, Trabit MH. Pharmacokinetic evaluation of UK-49858, a metabolically stable triazole antifungal drug in animals and humans. Antimicrob Agents Chemother 1985; 28; 648-53.
8. Shiba K, Saito A, Miyahara T. Pharmacokmetic evaluation of fluconazole in healthy volunteers. Jpn Antibiotics 1989; 42: 17-30.
9. Toon S, Ross CE, Gokat R, Rowland M. An assesment of the effects of impaired renal function and haemodialysis on the pharmacokinetic of fluconazole. Br J Clin Pharmacol 1990, 29: 221-6.
10. Nation LR, Sansom NL. Bioequivalence requirements for generic products. Pharmacol Ther 1994; 62: 41-55.
11. Sauter R, Steinijans VW, Diletti E, Bohm A, Schultz HU. Presentation of results from bioeqivalence studies. Int J Clin Pharmacol Ther Toxicol 1992; 30 (Suppl. 1): S7-S30.
12. Schuirmann DJ. A comparison of the two one-side tests procedure and the power approach for assessment the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657-80.
13. Farrow PR, Faulkner JK, Brammer KW. The pharmacokinetics of fluconazole. Symposium on Fluconazole: A Novel Advance in the Therapy for Systemic Fungal Infections. Dorado, Puerto Rico. Oct 8-9. Abstract no. 14-199, 1988.
14. Jezequel SG. Fluconazole: Interspecies scaling and aliometric relationships of pharmacokinetic properties. J Pharm Pharmacol 1994; 46: 196-9.